pubmed· e01.org

PubMed · PMID 28751069

Activity-Dependent Brain-Derived Neurotrophic Factor Release Is Required for the Rapid Antidepressant Actions of Scopolamine.

PMID 28751069Journal Biological psychiatryYear 2018Authors 7DOI 10.1016/j.biopsych.2017.06.017

  • Source PubMed
  • Journal Biological psychiatry
  • Year 2018
  • Authors Sriparna Ghosal; Eunyoung Bang; Wenzhu Yue; Brendan D Hare; Ashley E Lepack; Matthew J Girgenti; Ronald S Duman
  • Licence NLM/PubMed terms

Abstract

Brain-derived neurotrophic factor (BDNF) plays a key role in the pathophysiology and treatment of depression. Recent clinical studies demonstrate that scopolamine, a nonselective muscarinic acetylcholine receptor antagonist, produces rapid antidepressant effects in patients with depression. Rodent studies demonstrate that scopolamine increases glutamate transmission and synaptogenesis in the medial prefrontal cortex (mPFC).

Here we tested the hypothesis that activity-dependent BDNF release within the mPFC is necessary for the antidepressant actions of scopolamine. Behavioral effects of scopolamine were assessed in BDNF Val/Met knock-in mice, in which BDNF processing and release are impaired. In addition, intra-mPFC infusion of a BDNF-neutralizing antibody was performed to test the necessity of BDNF release in driving scopolamine-induced behavioral responses.

Further in vivo and in vitro experiments were performed to delineate BDNF-dependent mechanisms underlying the effects of scopolamine. We found that BDNF Met/Met mice have attenuated responses to scopolamine and that anti-BDNF antibody infusions into the mPFC prevented the antidepressant-like behavioral effects of scopolamine. In vitro experiments show that scopolamine rapidly stimulates BDNF release and tropomyosin receptor kinase B-extracellular signal-regulated kinase signaling.

Moreover, these effects require alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor activation and are blocked by neuronal silencing. Importantly, pretreatment with verapamil prevented scopolamine-induced behavioral responses and BDNF-tropomyosin receptor kinase B signaling, suggesting that these effects are dependent on activation of voltage-dependent calcium channels. The results identify an essential role for activity-dependent BDNF release in the rapid antidepressant effects of scopolamine.

Attenuation of responses in BDNF Met mice indicates that patients with the Met allele may be less responsive to scopolamine.

Record details

PMID28751069
PMCIDnot held
DOI10.1016/j.biopsych.2017.06.017
JournalBiological psychiatry
Year2018
AuthorsSriparna Ghosal; Eunyoung Bang; Wenzhu Yue; Brendan D Hare; Ashley E Lepack; Matthew J Girgenti; Ronald S Duman
Licencenot stated
MeSHAnimals; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Calcium Channels, L-Type; Cells, Cultured; Depressive Disorder; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Male; Mice, Transgenic; Motor Activity; Neurons; Rats, Sprague-Dawley; Receptor, Muscarinic M1; Receptor, trkB; Scopolamine; Synaptosomes; Time Factors; Verapamil; gamma-Aminobutyric Acid

Source record

Open the PubMed record. This page holds the abstract and citation fields for this PMID; no PMC full text is held for it.

Source
PubMed / NLM
PMID
28751069
Rendered
2026-11-21
Completeness
abstract and citation fields